Key Findings
- A 2020 meta-analysis (Asbaghi et al., 28 trials) found chromium supplementation was associated with reduced HbA1c (about −0.71%) and fasting plasma glucose (about −19 mg/dL) in type 2 diabetes.
- A 2015 meta-analysis (Yin & Phung, 14 trials, 875 participants) found most chromium forms showed NO statistically significant effect on HbA1c, with only a marginal fasting-glucose benefit from one form (brewer's yeast).
- Heterogeneity across trials was very high, and effects appear to depend on the chromium form and dose.
- Overall the evidence is mixed, and any glycemic benefit appears modest at best.